IPRP Working Groups

[...]
/working-group/bioequivalence-generics
2018-08-03
The Bioequivalence Working Group for Generics (BEWGG) covers the application and interpretation of bioequivalence requirements as well as information and procedures for the assessment of
[...]
/working-group/biosimilars
2018-06-05
The Biosimilars Working Group (BWG) provides meaningful outcome to promote public health through more affordable biosimilar products.   Mandate 1. General considerations The
[...]
/working-group/cell-therapy
2018-08-03
The Cell Therapy Working Group (CTWG)’s primary goals are open discussion and sharing of best practices for the regulation of cell and tissue-based therapies, as well as support of harmonization
[...]
/working-group/gene-therapy
2018-06-04
The Gene Therapy Working Group (GTWG)’s objective is to discuss emerging scientific developments and concerns for the regulation of Gene Therapy (GT) products and to share regional updates in
[...]
/working-group/identification-medicinal-products
2018-08-03
The Identification of Medicinal Products Working Group (IDMPWG)’s work is to ensure the awareness and understanding of the IDMP standards by pharmaceutical regulators, to clarify how and why these
[...]
/working-group/information-sharing-generics
2018-08-03
The Information Sharing Working Group for Generics (IWGG) is a pilot for the sharing of information on the evaluation of Generic Drug applications involving the Decentralised Procedure (DCP) and
[...]
/working-group/nanomedicines
2018-08-03
The Nanomedicines Working Group (NWG) works on the exchange of non-confidential information on nanomedicines and nanomaterial in drug products and borderline and combination products.  
[...]
/working-group/pharmacovigilance
2019-12-04
Following-on from discussions held at the previous meeting on real-world evidence and the use of non-conventional data sources for pharmacovigilance purposes, the MC decided in November 2019 to
[...]
/working-group/quality
2018-08-03
The Quality Working Group (QWG) identifies opportunities for regulatory convergence and information sharing by exchanging and discussing information from members’ organisation regarding issues of